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Human MicroRnAs Deregulation in cancer Molecular Mechanisms, Targets Diagnostic, Prognostic Marker
let-7 family (various) Downregulated in lung, breast, gastric, ovary, 
prostate and colon cancers, CLL, leiomyomas; 
miR-98 downregulated in head and neck cancer. 
Point mutation in let-7e transcript affects miRNA 
maturation.
Repress cell proliferation and growth. let-7f promotes 
angiogenesis. Targets: CCND1, CDC25a, CDC34, CDK6, CRD-
BP, DICER, HMGA2, HOXA9, IMP-1, ITGB3, MYC, RAS, TLR4.
SNP in K-RAS 3′ UTR (let-7a binding site) 
increases NSCLC risk (cancer predisposition). 
Low expression of let-7a-2 in lung and ovarian 
cancer and of let-7b in uveal melanoma (poor 
prognosis). let-7i affects chemotherapy potency. 
Intranasal delivery of let-7a reduces growth of 
Ras-induced mouse lung tumors.
let-7a-3 hypomethylated in lung adenocarcinoma; 
overexpressed in AML
let-7a represses NF2 and decreases chemotherapy-induced 
apoptosis in vitro. Target: CASP3.
miR-10b (2q31.1, 
intergenic)
Downregulated in breast cancer. Overexpressed 
in metastatic breast cancer (does not predict 
metastasis in early stages). 




intron 4 noncoding 
RNA DLEU2)
Downregulated in CLL, DLBCL, multiple myeloma, 
pituitary adenoma, prostate and pancreatic 
cancer. Germline mutations in B-CLL patients and 
in NZB mice that develop CLL-like disorder.
Induce apoptosis in leukemia cells. miR-16 regulates cell cycle 
by downregulating G0/G1 proteins. Targets: BCL2, CAPRIN1, 
CARD10, CCND1, CDK6, CDC27, CGI-38, CYCE, DMTF1, 
HMGA2, MCL1, MYB, NGN2, VEGF, WNT3A.
Low expression of miR-15a, miR-16 in de 
novo CLL (good prognosis). miR-16 modulates 
chemotherapy potency, sensitivity to vincristine 
in gastric cancer (predicts response).





(13q31.3, intron 3 
C13orf25)
Overexpression in lung and colon cancer, 
lymphoma, multiple myeloma, medulloblastoma
miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 increase tumor 
growth and tumor vascularization; miR-20a is antiapoptotic; 
transgenic miR-17-92 mice develop lymphoproliferative disease 
and autoimmunity. Targets: AIB1, AML1, BIM1, CTGF, CDKN1A, 
E2F1, E2F2, E2F3, HIF-1A, PTEN, TGFBR2, TSP1, Rb2/P130.
High plasma levels of miR-92 discriminate 
colorectal and gastric cancer from normal 
(diagnostic)
LOH at miR-17-92 locus in melanoma (20%), 
ovarian (16.5%) and breast (21.9%) cancer
miR-17 reduces breast cancer cell proliferation. miR-20 induces 
senescence via LRF. Targets: AIB1, CYCD1.
miR-106b-93-25 
cluster (7q22.1)
Overexpression in gastric, colon, and prostate 
cancer, neuroblastoma, multiple myeloma
Reduces apoptotic response after TGFβ stimulation via BIM. 
Targets: CDKN1A, E2F1, BIM.
miR-21 (17q23.1, 
3’UTR TMEM49)
Overexpression in glioblastoma, breast, lung, 
prostate, colon, stomach, esophageal, and 
cervical cancer, uterine leiomyosarcoma, DLBCL, 
head and neck cancer
miR-21 knockdown induces apoptosis in glioblastoma. miR-21 
induces invasion, metastasis in colorectal cancer. Targets: 
BCL2, MASPIN, PDCD4, PTEN, TPM1, RECK, RASA1.
miR-21 high expression in colon, breast, and 
pancreatic cancer (poor prognosis). miR-21 high 
expression in de novo DLBCL (good prognosis). 
miR-21 modulates chemosensitivity in NCI60 cells. 
miR-29 family 
(various)
Downregulation in CLL, colon, breast, and lung 
cancer, and cholangiocarcinomas
Induce aberrant methylation in lung cancer via DNMT3A,B; 
induce apoptosis via p53 and MCL1. Targets: CDC42, 
DNMT3A, B, MCL1, PIK3R1, TCL1.
miR-29c low expression correlates with short 
time from diagnosis to therapy in CLL (poor 
prognosis)




Downregulated in pancreatic cancer and 
Burkitt’s lymphoma without MYC translocation. 
Hypermethylation of miR-34b,c in colon cancer.
miR-34a induces upregulation of p53, downregulation of E2F in 
colon cancer. Targets: BCL2, CCND1, CCNE2, CDK4,6, MYC, 
DLL1, E23, Notch1, MYCN, MET, HMGA2, SIRT1.
miR-34a low expression in CLL associated 




Downregulation in prostate cancer, hepatocellular 
carcinoma, and bladder cancer
Alterations in global chromatin structure via repression of EZH2. 
Targets: COX2, EZH2, MCL1.
miR-122a (18q21.31 
intergenic)
Downregulation in hepatocellular carcinoma Targets: CAT-1, CCNG1
miR-124a family 
(various)
Hypermethylation in colon, breast, gastric, and 
lung cancer, leukemia, lymphoma




Downregulation in glioblastoma, breast, prostate 
and ovarian cancer
Targets: ERBB2, ERBB3, LIN28, LIN41, TNFSF4
Upregulation in myelodysplastic syndrome and 








Downregulated in colon adenoma/carcinoma, 
in breast, lung, and cervical cancer, in B cell 
malignancies
miR-143, miR-145 precursor sequences abnormally processed 
in colon cancer. Targets: MYC, ERK5, HOXA9, KRAS, PARP8.
miR-155 (21q21.3, 
exon 3 ncRNA BIC)
Overexpressed in pediatric Burkitt’s lymphoma, 
Hodgkin’s lymphoma, primary mediastinal 
lymphoma, DLBCL, breast, lung, colon, 
pancreatic cancer
Pre-B cell proliferation, lymphoblastic leukemia/high-grade 
lymphoma in miR-155 transgenic mice. Targets: AGTR1, AID, 
IKBKE, TP53INP1.
High expression of miR-155 in lung cancer, 
DLBCL, and aggressive CLL (poor prognosis)
miR-181 family 
(various)
Overexpressed in breast, pancreas, prostate 
cancer
MYCN regulates transcription of miR-181 cluster. Targets: 
HOXA11, TCL1.
Low expression of miR-181 in aggressive CLL 




Overexpressed in CLL, thyroid papillary 
carcinoma, glioblastoma. Downregulated in AML.
Promotes cancer cell proliferation; miR-221, miR-222 impair 




Downregulated in clear-cell carcinoma, 
metastatic breast cancer
Promote invasion together with miR-205. Downregulation 
of miR-200 family (and miR-205) directly involved in TGFβ-




Overexpression of miR-373 in testicular cancer Indirectly antagonize p53-mediated CDK inhibition during RAS-
induced senescence. miR-373 transactivates CDH1 transcription 
by targeting the promoter region. Targets: LATS2, CD44.
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MicroRNAs (miRNAs) (http://microrna.sanger.ac.uk/sequences/) are 19 to 25 nucleotide-long noncoding RNA molecules that regulate gene expression both at the level 
of messenger RNA degradation and translation. MicroRNAs are typically excised from a 60 to 110 nucleotide-long hairpin precursor (fold-back) RNA structure (pre-
miRNA) by the RNase III enzyme Dicer and are incorporated into the RNA-induced silencing complex (RISC). The pre-miRNA sequence is transcribed from a larger Pol II 
primary transcript (pri-miRNA) processed by Drosha and exported from the nucleus to the cytoplasm. Strongly conserved among distantly related organisms (including 
invertebrates, vertebrates, and plants), miRNAs are involved in a variety of biological processes including cell cycle regulation, differentiation, development, metabo-
lism, neuronal patterning, and aging. Alterations in miRNA expression are involved in the initiation, progression, and metastasis of human tumors. Functional germline 
mutations in the miR-15a and miR-16-1 cluster are associated with familial chronic lymphocytic leukemia (CLL) and breast cancer, whereas a common SNP in pre-miR-
146a decreases mature miRNA expression and predisposes to papillary thyroid carcinoma. Furthermore, miR-155 transgenic mice show proliferation of pre-B cells and 
develop lymphoblastic leukemia/high-grade lymphoma. Mice overexpressing miR-17-92 in lymphocytes develop lymphoproliferative disease and autoimmunity and die 
prematurely. During cancer progression, dramatic overexpression or downregulation of mature and/or precursor miRNAs occurs in most tumors. The miRNAs miR-10b, 
miR-373, and miR-520c promote tumor invasion and metastasis, whereas miR-335, miR-206, and miR-126 are suppressors of breast cancer metastasis. The differen-
tial expression of miRNA genes in malignant compared with normal tissue can be explained by three different mechanisms: location of miRNAs in cancer-associated 
genomic regions, epigenetic mechanisms, and alterations in the miRNA processing or transcription machinery. The let-7 miRNA family and the miR-15a/miR-16-1 clus-
ters are located in loci deleted in lung cancer and CLL, respectively; the miR-17-92 genomic locus is amplified in B cell lymphoma. The miRNA miR-127 is re-expressed 
after DNA demethylation and histone deacetylase inhibition in cancer cells; miR-124a is transcriptionally inactivated by hypermethylation of CpG islands in different 
tumor cell lines. Impaired miRNA processing enhances cellular transformation and tumorigenesis, as shown by the conditional deletion of Dicer1, which increases tumor 
development in a K-Ras-induced mouse model of lung cancer. Moreover, reduced expression of Dicer and Drosha has been observed in various human cancers. Several 
transcription factors regulate the expression of miRNAs, e.g., the tumor suppressor protein p53 regulates the expression of miR-34 family members, MYC is a negative 
regulator of miRNA expression, STAT3 regulates miR-21 expression at the transcriptional level, and Twist transactivates miR-10b transcription.
The functional consequences of altered patterns of miRNA expression are just starting to be understood. Self-sustaining growth signals can be induced by miR-21 
overexpression, which is responsible for PTEN repression and loss of negative regulation by AKT kinase. Insensitivity to antigrowth signals is achieved by inhibition of 
E2F transcription factors caused by overexpression of the miR-17-92 cluster on chromosome 13q31.1 and by overexpression of the miR-106b-25 cluster on chromo-
some 7q22.1. Specifically, miR-20a inhibits expression of E2F2 and E2F3, whereas miR-17-5p, miR-20a, miR-106b, and miR-92 inhibit expression of E2F1. Modulation 
of apoptosis may occur by direct regulation of miRNAs by proapoptotic (p53 and miR-34 family) or antiapoptotic (IL6/STAT3 and miR-21) pathways, or by direct tar-
geting of antiapoptotic (BCL2, MCL1 proteins and the miR-15/16 cluster) or proapoptotic (TP53BP1 and miR-155) proteins. Deregulation of telomerase activity can be 
achieved in tumors through reduced expression of miR-138, which represses translation of TERT mRNA and induces unrestricted proliferation. Blood vessel formation 
(angiogenesis) is regulated by miRNAs, and hypoxia is a proven regulator of miRNA expression. The oncomiR-17-92 cluster that is regulated by MYC participates in 
the creation of a more aggressive, richly perfused tumor phenotype, whereas hypoxia contributes to the modulation of miRNA expression (including miR-210) partly by 
direct transcriptional activation of HIF-1 by specific miRNAs. Due to the specificity of targets and regulatory mechanisms, an miRNA may be an oncogene in one tumor 
type but a tumor suppressor in another.
MicroRNA expression profiling of human tumors has identified signatures that are associated with diagnosis, prognosis, and treatment efficacy. Distinct miRNA fin-
gerprints characterize highly aggressive cancers, e.g., overexpression of miR-155 and downregulation of let-7 miRNAs in lung cancer cells indicates a poor prognosis. 
Furthermore, miRNA profiling can be used to successfully classify poorly differentiated tumors, including those with an unknown primary site. For example, high expres-
sion of miR-21 is associated with poor survival and a poor therapeutic response to chemotherapy in colon cancer patients. The development of agents that block or 
mimic the expression and functions of miRNAs may represent a new therapeutic option for treating cancer patients.
Abbreviations
AID, activated induced cytidine deaminase; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; EMT, epithelial-
mesenchymal transition; LOH, loss of heterozygosity; LRF, leukemia/lymphoma-related factor; NSCLC, non-small cell lung cancer; NZB, New Zealand Black; TTP, 
ADAM metallopeptidase with thrombospondin type I motif.
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